Programs

To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Clinical Center Drug Donations

The Clinical Center In-Kind Drug Donation Program provides pharmaceuticals that are donated through the public-private partnership coordinated by the FNIH to the NIH Clinical Center.

John Laws Decker Memorial Fund

The Dr. John Laws Decker Memorial Fund honors the late NIH Clinical Center Director through the annual John Laws Decker Memorial Lecture and the Distinguished Clinical Teacher's Award.

Dr. John L. Barr Memorial Fund

The Dr. John L. Barr Memorial Fund supports the Intramural Research Training Award (IRTA) fellowship program at the Clinical Center's Pain and Palliative Care Service.

NIH Medical Research Scholars Program

The MRSP is a one-year intensive training program on the NIH campus for up to 50 medical, dental and veterinary students to engage them in research early in their careers.

Biomarkers Consortium - The Performance of Novel Cardiac Biomarkers in the General U.S. Population

The Biomarkers Consortium’s Novel Cardiac Biomarkers in the General US Population (the Cardiac Troponin Project) seeks to define the reference ranges and to generate the epidemiologic basis for the use of several significant novel cardiac and related biomarkers for cardiovascular risk stratification in the general U.S. population. The program will measure a panel of biomarkers in almost 30,000 individuals in a national study. The project will provide key reference data regarding novel biomarkers for cardiovascular risk stratification and inform U.S. clinical and laboratory guidelines.

Biomarkers Consortium - Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers

The Biomarkers Consortium’s Kidney Safety Project aims to advance clinical regulatory qualification and broader acceptance of new translational biomarkers that outperform sCr and BUN for monitoring kidney safety to support early clinical drug development.